A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms
Latest Information Update: 07 Feb 2023
At a glance
- Drugs LP 002-Lepu Biopharma (Primary) ; Cisplatin; Fluorouracil; OH 2
- Indications Adenocarcinoma; Carcinoma; Digestive system neoplasms; Gastric cancer; Neuroendocrine tumours; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Taizhou HoudeAoke Biomedical
Most Recent Events
- 07 Jun 2022 Results (n=30) assessing safety and pathological response of gastroesophageal cancer pts receiving LP002, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 18 Feb 2021 New trial record